Related references
Note: Only part of the references are listed.Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
Joachim Stangier
CLINICAL PHARMACOKINETICS (2008)
Drug–drug interaction with statins
Alberto Corsini et al.
Expert Review of Clinical Pharmacology (2008)
Dabigatran with or without concomitant Aspirin compared with Warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)
Michael D. Ezekowitz et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial
Bengt I. Eriksson et al.
LANCET (2007)
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
Joachim Stangier et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Do statins have an antiarrhythmic activity?
M. S. Kostapanos et al.
CARDIOVASCULAR RESEARCH (2007)
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
BI Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
The pharmacology and management of the vitamin K antagonists
J Ansell et al.
CHEST (2004)
Antithrombotic therapy for venous thromboembolic disease
HR Büller et al.
CHEST (2004)
Clinical pharmacokinetics of atorvastatin
H Lennernas
CLINICAL PHARMACOKINETICS (2003)
Structure-based design of novel potent nonpeptide thrombin inhibitors
NH Hauel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Share Paper
